ANZCTR search results

This study will explore the impact of general practice-initiated SMS recall messages (with and without an additional nudge message) on increasing attendance at GP clinics and increasing CVD risk assessment. The trial design will be a three-armed randomised control trial. The level of analysis will be general practice clinics. Practices in the two active arms will be provided with an information package (constituting a recall SMS with an embedded link to health promotion resources) to be sent to appropriate patients Active arm 2 will be provided with an additional nudge message (with embedded link to health promotion material) to be sent two weeks after the recall message is sent. The control arm practices will be asked to maintain care as usual for a three-month follow up period. Following the 3 month observation period, the practices in the control arm will be provided with all materials and support provided to the active arm allowing them to provide identical information to their patients. The practices will be randomised using a pseudo random number generator (RNG) to assign participating practices to one of three groups.

This study will investigate whether the expectation of threat influences sensitivity to temperature in healthy people. All participants will have their warmth detection and heat-pain thresholds on the back of their hand, forearm and upper arm measured. Participants will then be randomised into two groups: one will be told their hand will be immersed (only as far as the wrist) in green coloured, neutral temperature water (control group). The other group will be told their hand will be placed in a bucket of painfully cold water (intervention). Pressure pain-threshold will be re-measured post randomisation. We hypothesise that the cold water group will demonstrate reduced heat-pain threshold and increased warmth detection thresholds, suggesting an increase in sensitivity to noxious stimulation and reduced sensitivity to non-noxious stimulation, after being told they are going to have their arm immersed in cold water compared to those who are randomised into the neutral temperature water. We also hypothesise that the difference will be greatest at the hand as that is the rest of the arm is not expected to be immersed.

This study will investigate whether the expectation of threat influences sensitivity to temperature in healthy people. All participants will have their warmth detection and heat-pain thresholds on the back of their forearm measured. Participants will then be randomised into two groups: one will be told their arm will be immersed in green coloured, neutral temperature water (control group). The other group will be told their hand will be placed in a bucket of painfully cold water (intervention). Pressure pain-threshold will be re-measured post randomisation. We hypothesise that the cold water group will demonstrate reduced heat-pain threshold and increased warmth detection thresholds, suggesting an increase in sensitivity to noxious stimulation and reduced sensitivity to non-noxious stimulation, after being told they are going to have their arm immersed in cold water compared to those who are randomised into the neutral temperature water.

This study will investigate whether the expectation of threat influences sensitivity to pressure in healthy people. All participants will have their pressure-pain threshold on the back of their forearm measured using an algometer. Participants will then be randomised into two groups: one will be told their arm will be immersed in green coloured, neutral temperature water (control group). The other group will be told their hand will be placed in a bucket of painfully cold water (intervention). Pressure pain-threshold will be re-measured post randomisation. We hypothesise that the cold water group will demonstrate reduced pressure pain thresholds, suggesting an increase in sensitivity, after being told they are going to have their arm immersed in cold water compared to those who are randomised into the neutral temperature water.

This six month observational study was undertaken to better understand the differences in the pharmacokinetics (if any) of children who receive secondary prophylaxis with benzathine penicillin G in Aboriginal individuals aged 5-21, for acute rheumatic fever and/or rheumatic heart disease. It is well established that plasma concentrations of penicillin vary greatly. To date no studies have been undertaken in an Australian Aboriginal cohort living in the Northern Territory. Other aspects such as breakthrough infections and inflammatory response will be assessed through repeated throat or skin swabs and measurements of anti streptolysin O titres throughout the study.

Paediatric spinal cord disorder (SCD) is a devastating occurrence that carries severe physiological consequences. Because children are still developing, the effects of injury differ significantly from those seen in adults with SCD. Among these are the effects on bone health in children with SCD. The loss of neural input and compromised musculoskeletal interaction causes the disruption of bone growth below the injury site. This poses significant implications for later life. Despite the significant negative effect of SCD on bone health in children, there is a lack of evidence based clinical practice guidelines for treatment of bone health, and there are significant variations in clinical practice. This study aims to improve our understanding of bone development following SCD using multiple imaging modalities, which will allow the development of consistent, evidence-based guidelines, thus improving future treatment of these patients.

Raised blood pressure (BP) is the leading but modifiable risk factor for preventable death and physical inactivity can substantially lower BP. However, participation in physical activity is low in Australia. To overcome this, people with hypertension in Australia can be referred to a Medicare-subsidised Accredited Exercise Physiologist (AEP) to receive individualised exercise counselling. Yet, the uptake of this service remains low, in part due to a lack of awareness of the benefits of physical activity. Thus, this randomised controlled trial aims to investigate the feasibility and efficacy of an online 12-week exercise physiologist intervention for improving fitness and reducing high BP in people who are diagnosed with hypertension compared to the control group who will receive usual care.

This clinical trial aims to investigate the effectiveness of a Cognitive Behavioural Therapy (CBT) program delivered via a smartphone application (called ClearlyMe) for improving mental health outcomes in Australian adolescents (aged 12 to 17 years) with mild to moderate depressive symptoms. This trial will examine the effectiveness of a new CBT smartphone application (ClearlyMe) for reducing depressive symptoms in adolescents when compared to guided use and an active-attention matched control condition. The primary research questions that this trial seeks to address are: 1. What is the effectiveness of ClearlyMe (both self-directed and guided use) for reducing depressive symptoms? Secondary research questions include: 2. What is the effectiveness of ClearlyMe for reducing anxiety symptoms, psychological distress, rumination, and improving emotional wellbeing, quality of life, emotion regulation, and CBT skill acquisition? 3. Does guided support lead to greater engagement with and completion of the ClearlyMe app when compared to self-directed use? 4. Do factors such as gender, age, baseline mental health history or symptom severity, perceived need for care, or openness to digital mental health moderate the improvements in depressive symptoms found among users of ClearlyMe? 5. Do factors such as rumination, emotion regulation, CBT skill acquisition, digital therapeutic alliance and program engagement/completion mediate the improvements in depressive symptoms found among users of ClearlyMe?

There is a need for better treatments for spasticity in cerebral palsy (CP). Spasticity is a common target for many established treatments for CP such as Botulinum toxin A injection, oral baclofen, intrathecal baclofen pump implantation, and selective dorsal rhizotomy surgery. For over 40 years there have been attempts to use spinal cord stimulation (SCS) to treat spasticity, yet its role as a treatment in cerebral palsy has been limited. Recent advances in technology have enabled closed-loop control of SCS devices meaning that targeted electrical stimulation of the spinal cord can now be used in a real world setting with a device that is not adversely affected by sudden movements in posture, such as from muscle spasms. This technological advance combined with evidence relating to the importance of early intervention in cerebral palsy have led to the initiation of this trial. The Liberty Trial investigates the use of closed loop spinal cord stimulation in the treatment of lower limb spasticity for children living with spasticity. Children between 6 and 16 years with CP and spasticity predominately affecting at least one lower limb and who are candidates for SCS will be enrolled. The total study duration is 36 months. The study enrolment period is expected to be 12 months, and participants implanted with the investigational device will be followed for 24 months from implant. Treatment safety will be investigated, and efficacy will be determined by evaluation of the outcome measures at determined time-points using defined performance criteria. Additionally; the patient demographics, diagnosis and prior anti-spasticity treatments will be documented. The intervention in this trial consists of the implantation of an electronic medical device, a spinal cord stimulator, known as the EvokeTM Closed Loop Stimulator and leads, to reduce lower limb spasticity in children living with cerebral palsy. Intensive physiotherapy will accompany the intervention to try to improve lower limb function and mobility. This will be performed face to face by a physiotherapist experienced in post-spasticity intervention rehabilitation (i.e. botulinum toxin and selective dorsal rhizotomy). The principles of Goal Directed Therapy will be followed to compare the ability of the participants to achieve meaningful functional goals before and after the intervention.

Loss of appetite, known as anorexia, is a distressing symptom for people with cancer resulting in considerable involuntary weight loss, reduced physical activity, poor prognosis and death. To date, there are limited treatment options and no registered therapy for the treatment of cancer anorexia. Patients with small cell lung cancer have high prevalence of weight loss. The aim of this study is to determine whether it is feasible and desirable to conduct a study of anamorelin for the treatment of anorexia symptoms in patients with small cell lung cancer. – Who is it for? You may be eligible for this study if you are aged 18 years or older, have been diagnosed with small cell lung cancer (local or advanced) and have planned systemic therapy OR have first recurrence of disease after at least 6 months of documented disease-free following successful treatment, and you are at risk of developing anorexia based on a dietary score. Study details Participants who choose to enrol in this study will be randomly allocated (by chance, similar to flipping a coin) to receive 12 weeks of either anamorelin or placebo as an oral tablet. Participants will be assessed [~4 weekly] by the study team for the duration of treatment to monitor safety, feasibility and acceptability of study procedures and medication, and suitability of outcome measures for a full trial. Participants will be asked to undergo some laboratory tests and scans and to complete a study diary and a number of questionnaires at 1, 4, 8 and 12 weeks post-treatment commencement. These will involve answering questions regarding general well-being and quality of life, pain, nausea, side effects, capability in daily functions and dietary intake. Participants will also be asked to monitor their physical activity using a pedometer or mobile app. At the end of the 12 week study, all participants will be invited to continue taking their allocated medication for another 12 weeks, with additional questionnaires and assessments to be undertaken at 18 and 24 weeks after starting the medication. This extension stage is completely optional and up to the participant. It is hoped that this study will help clinicians to evaluate the safety, feasibility and desirability of anamorelin as a treatment for cancer-related anorexia and for a phase III trial.